Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Astellas Pharma, Inc. (OTC: ALPMY).

Full DD Report for ALPMY

You must become a subscriber to view this report.


Recent News from (OTC: ALPMY)

Astellas Acquires Potenza Therapeutics
TOKYO and NORTHBROOK, Ill. , Dec. 14, 2018 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa , Ph.D., "Astellas") today announced that it exercised, and closed on its exclusive option to acquire Potenza Therapeutics, Inc. ("Potenza") on ...
Source: PR Newswire
Date: December, 14 2018 13:00
Astellas Launches XOSPATA® (gilteritinib) in the U.S. for the Treatment of Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) with a FLT3 Mutation
TOKYO , Dec. 10, 2018 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa , Ph.D. "Astellas") today announced that XOSPATA ® (generic name: gilteritinib) is now available for prescription in the United States for the treatment of adult patients...
Source: PR Newswire
Date: December, 10 2018 21:00
Astellas Presents Updated Results from Phase 1 Study of Gilteritinib Plus Chemotherapy in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)
TOKYO , Dec. 3, 2018 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa , Ph.D. "Astellas") today announced updated results from a Phase 1 study of gilteritinib in combination with induction and consolidation chemotherapy in patients newly diagnosed w...
Source: PR Newswire
Date: December, 03 2018 11:15
Cancer Research Highlight: Astellas Takes Us Into A New Generation Of Therapy For AML
Please note that I am affiliated with Avisol Capital Partners and their Total Pharma Tracker service. They have also covered the companies in this article in their writings, and I wanted to make readers aware of the potential for overlapping coverage. If you've followed my news cov...
Source: SeekingAlpha
Date: December, 02 2018 09:58
XOSPATA® (gilteritinib) Approved by U.S. FDA for Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) with a FLT3 Mutation
TOKYO , Nov. 28, 2018 /PRNewswire/ --   Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa , Ph.D. "Astellas") today announced that the U.S. Food and Drug Administration (FDA) approved XOSPATA ® (generic name: gilteritinib) for the treatment of adult patients w...
Source: PR Newswire
Date: November, 28 2018 19:25
Cancer Research Highlight: AbbVie And Pfizer Blitz Acute Myeloid Leukemia
Please note that I am affiliated with Avisol Capital Partners and their Total Pharma Tracker service. They have also covered the companies in this article in their writings, and I wanted to make readers aware of the potential for overlapping coverage. Until very recently, patients ...
Source: SeekingAlpha
Date: November, 27 2018 08:00
Astellas Global Health Foundation Launches
TOKYO and NORTHBROOK, Ill. , Nov. 20, 2018 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503) (President and CEO: Kenji Yasukawa, Ph.D., "Astellas") announced the launch of the Astellas Global Health Foundation (AGHF), a new international philanthropic organization dedicated to ...
Source: PR Newswire
Date: November, 20 2018 10:00
Astellas to Present New Data on Gilteritinib in Multiple Populations of FLT3 Mutation-Positive Acute Myeloid Leukemia (AML) Patients at the 2018 American Society of Hematology (ASH) Annual Meeting
TOKYO , Nov. 19, 2018 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503) (President and CEO: Kenji Yasukawa , Ph.D. "Astellas") today announced it will present new data in Acute Myeloid Leukemia (AML) research at the 60th American Society of Hematology (ASH) Annual Meeting, taking place D...
Source: PR Newswire
Date: November, 19 2018 09:00
Astellas Receives Positive CHMP Opinion for XTANDI® (enzalutamide) for Adult Men with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer
TOKYO and CHERTSEY, England , Sept. 24, 2018 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa , Ph.D., "Astellas") announced today that The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a posit...
Source: PR Newswire
Date: September, 24 2018 09:00
Arvinas Holding Prepares Terms For $100 Million IPO
Quick Take Arvinas Holding ( ARVN ) intends to raise $100 million from the sale of its common stock in a U.S. IPO, per an amended registration statement . The company is advancing a pipeline of drug candidates for the treatment of various cancers. ARVN has enviable licensing partnership...
Source: SeekingAlpha
Date: September, 20 2018 14:06

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-1714.4214.42514.5914.38105,665
2018-12-1414.5114.5314.6214.5187,824
2018-12-1314.6814.8114.8814.6888,141
2018-12-1214.6114.65514.7414.6171,817
2018-12-1114.6914.5214.6914.41269,797

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-1736,753105,66534.7826Cover
2018-12-1415,91287,42918.1999Cover
2018-12-136,46188,1417.3303Cover
2018-12-1210,66267,20815.8642Cover
2018-12-1155,441269,79720.5492Cover

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on ALPMY.


About Astellas Pharma, Inc. (OTC: ALPMY)

Logo for Astellas Pharma, Inc. (OTC: ALPMY)

Not available

 

Contact Information

 

 

Current Management

  • Masao Yoshida / CEO, President

Current Share Structure

     


    Recent Filings from (OTC: ALPMY)

    Filing to become effective immediately upon filing
    Filing Type: F-6EFFiling Source: edgar
    Filing Date: December, 21 2017
    Post-effective amendment to a previously filed F-6
    Filing Type: F-6 POSFiling Source: edgar
    Filing Date: September, 29 2017

     

     


    Daily Technical Chart for (OTC: ALPMY)

    Daily Technical Chart for (OTC: ALPMY)


    Stay tuned for daily updates and more on (OTC: ALPMY)

    It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

    More to come on (OTC: ALPMY)

    Do your DD and if you choose, be ready to go!


     

    The Research: All source information contained in this email is from the public sources mentioned below.

     

     
     

    Thank you

    DD Report
    @DDReports

     

     


    Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in ALPMY is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of ALPMY and does not buy, sell, or trade any shares of ALPMY. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/